PMID- 38155626
OWN - NLM
STAT- MEDLINE
DCOM- 20240101
LR  - 20240101
IS  - 2186-3326 (Electronic)
IS  - 0027-7622 (Print)
IS  - 0027-7622 (Linking)
VI  - 85
IP  - 4
DP  - 2023 Nov
TI  - T cell receptor-engineered T cells derived from target human leukocyte 
      antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia 
      relapse following allogeneic hematopoietic cell transplantation.
PG  - 779-796
LID - 10.18999/nagjms.85.4.779 [doi]
AB  - Human leukocyte antigen (HLA)-DPB1 antigens are mismatched in approximately 70% 
      of allogeneic hematopoietic stem cell transplantations (allo-HSCT) from HLA 10/10 
      matched unrelated donors. HLA-DP-mismatched transplantation was shown to be 
      associated with an increase in acute graft-versus-host disease (GVHD) and a 
      decreased risk of leukemia relapse due to the graft-versus-leukemia (GVL) effect. 
      Immunotherapy targeting mismatched HLA-DP is considered reasonable to treat 
      leukemia following allo-HCT if performed under non-inflammatory conditions. 
      Therefore, we isolated CD4(+) T cell clones that recognize mismatched HLA-DPB1 
      from healthy volunteer donors and generated T cell receptor (TCR)-gene-modified T 
      cells for future clinical applications. Detailed analysis of TCR-T cells 
      expressing TCR from candidate clone #17 demonstrated specificity to myeloid and 
      monocytic leukemia cell lines that even expressed low levels of targeted HLA-DP. 
      However, they did not react to non-hematopoietic cell lines with a substantial 
      level of targeted HLA-DP expression, suggesting that the TCR recognized antigenic 
      peptide is only present in some hematopoietic cells. This study demonstrated that 
      induction of T cells specific for HLA-DP, consisting of hematopoietic cell 
      lineage-derived peptide and redirection of T cells with cloned TCR cDNA by gene 
      transfer, is feasible when using careful specificity analysis.
FAU - Katsuyama, Naoya
AU  - Katsuyama N
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Kawase, Takakazu
AU  - Kawase T
AD  - Department of Hematology and Oncology, Research Institute for Radiation Biology 
      and Medicine, Hiroshima University, Hiroshima, Japan.
AD  - Department of Immune Regenerative Medicine, International Center for Cell and 
      Gene Therapy, Fujita Health University, Toyoake, Japan.
FAU - Barakat, Carolyne
AU  - Barakat C
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Mizuno, Shohei
AU  - Mizuno S
AD  - Division of Hematology, Department of Internal Medicine, Aichi Medical 
      University, Nagakute, Japan.
FAU - Tomita, Akihiro
AU  - Tomita A
AD  - Department of Hematology, Fujita Health University School of Medicine, Toyoake, 
      Japan.
FAU - Ozeki, Kazutaka
AU  - Ozeki K
AD  - Department of Hematology and Oncology, JA Aichi Konan Kosei Hospital, Konan, 
      Japan.
FAU - Nishio, Nobuhiro
AU  - Nishio N
AD  - Center for Advanced Medicine and Clinical Research, Department of Advanced 
      Medicine, Nagoya University Hospital, Nagoya, Japan.
AD  - Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Sato, Yoshie
AU  - Sato Y
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Kajiya, Ryoko
AU  - Kajiya R
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Shiraishi, Keiko
AU  - Shiraishi K
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Takahashi, Yoshiyuki
AU  - Takahashi Y
AD  - Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Ichinohe, Tatsuo
AU  - Ichinohe T
AD  - Department of Hematology and Oncology, Research Institute for Radiation Biology 
      and Medicine, Hiroshima University, Hiroshima, Japan.
FAU - Nishikawa, Hiroyoshi
AU  - Nishikawa H
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
FAU - Akatsuka, Yoshiki
AU  - Akatsuka Y
AD  - Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Nagoya J Med Sci
JT  - Nagoya journal of medical science
JID - 0412011
RN  - 0 (HLA-DPB1 antigen)
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Humans
MH  - T-Lymphocytes
MH  - Transplantation, Homologous
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Leukemia/therapy
MH  - HLA-DP beta-Chains/genetics
MH  - Chronic Disease
MH  - Recurrence
MH  - Peptides
MH  - Receptors, Antigen, T-Cell/genetics
PMC - PMC10751490
OTO - NOTNLM
OT  - GVHD
OT  - TCR-T
OT  - allogeneic transplantation
OT  - leukemia
COIS- Y.A. received honoraria and research funding from Bristol-Myers Squibb. All other 
      authors declare no competing financial interests.
EDAT- 2024/01/02 10:02
MHDA- 2024/01/02 11:44
PMCR- 2023/11/01
CRDT- 2023/12/29 03:34
PHST- 2022/07/13 00:00 [received]
PHST- 2023/01/26 00:00 [accepted]
PHST- 2024/01/02 11:44 [medline]
PHST- 2024/01/02 10:02 [pubmed]
PHST- 2023/12/29 03:34 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - 10.18999/nagjms.85.4.779 [doi]
PST - ppublish
SO  - Nagoya J Med Sci. 2023 Nov;85(4):779-796. doi: 10.18999/nagjms.85.4.779.